Table 2 Prevalence of resistance associated mutations to non-nucleoside reverse transcriptase inhibitors (NNRTI) and nucleoside reverse transcriptase inhibitors (NRTI) in 220 HIV-infected infants identified over 3 survey years categorised according to infant PMTCT exposure
Infant PMTCT exposure: | n/N (%) with NNRTI mutations | n/N (%) with NRTI mutations |
|---|---|---|
Maternal ART plus infant NVP ± AZT | 25/34 (74%) | 5/34 (15%) |
Maternal ARV plus infant NVP ± AZT | 43/63 (68%) | 1/63 (2%) |
Infant NVP ± AZT only | 17/26 (65%) | 1/26 (4%) |
Other maternal and/or infant ARV | 6/15 (40%) | 1/15 (7%) |
No/unknown maternal and/or infant ARV exposure | 21/82 (26%) | 2/82 (2%) |
Total | 112/220 (51%) | 10/220 (5%) |